Brugada Syndrome Market – Global Overview and Forecast (2023-2029)

Brugada Syndrome Market size was valued at US$ 1.40 Bn. in 2022 and the total Brugada Syndrome revenue is expected to grow at 6.5% through 2022 to 2029, reaching nearly US$ 2.18 Bn.
Brugada Syndrome Market Overview:
Brugada syndrome is a disorder in which the heart's regular rhythm is interrupted sometimes resulting in chronic heart disease or failure. This condition can cause abnormal heart rhythms in the bottom chambers of the heart otherwise known as ventricles, a condition known as ventricular arrhythmia. If left untreated, abnormal heartbeats can lead to fainting (syncopal episode), seizures, breathing difficulties, and even death. These difficulties usually happen while the person is sleeping or relaxing. Preventive actions such as avoiding exacerbating drugs and lowering fever are among the Brugada syndrome remedies. An implanted cardioverter-defibrillator may be used as part of the therapy if necessary.To know about the Research Methodology :- Request Free Sample Report

Brugada syndrome has gone from being an uncommon condition to becoming the second leading cause of mortality among young adults in several nations, after only car accidents. The condition is linked with a significant risk of sudden cardiac mortality in young and otherwise healthy adults, but less commonly in babies and children, and is electrocardiographically defined by unique Pulmonary hypertension in the right precordial leads.

In this report, the Brugada Syndrome market's growth reasons, as well as the market's many segments (Treatment, Drugs, End-User, and Region), are discussed. Data has been given by market players, regions, and specific requirements. This market report includes a comprehensive overview of all the significant improvements that are presently prevailing in all market segments. Key data analysis is presented in the form of statistics, infographics, and presentations. The study discusses the Brugada Syndrome market's Drivers, Restraints, Opportunities, and Challenges. The report helps to assess the market growth drivers and determines how to use these drivers as a tool. The report also helps to rectify and resolve issues related to the global Brugada Syndrome market situation.
Brugada Syndrome Market Dynamics:
The primary driver of the market is the fact that cardiovascular transplants have long waiting lists. Due to an increase in the frequency of heart failure in recent years, the demand for heart transplantation has surged dramatically. However, a global scarcity of suitable organs for transplantation has developed from the inability to fulfill current demand. According to the National Database of the Health Resources and Services Administration of the United States, there were around 4150 candidates on the heart transplant waiting list as of March 2022.

Significant disparities in the number of volunteers and patients on waiting lists have been seen even at the country level. In Australia, for example, over 1,760 people were on the waitlist for a heart transplant in 2022, but only over 500 volunteers were available. According to the Transplant Activity Report 2022, the number of patients on waiting lists for a heart transplant had climbed by 120 percent since 2010.

Following the global pandemic of COVID-19, there have been considerable changes in the medical system. Several nations have agreed to postpone elective surgery in the cardiovascular care industry to reduce the risk of infection. Prospective cardiac procedures have been postponed in the United Kingdom because of the impact of COVID-19 on medical systems. This is due to a rearrangement of critical care services and the incalculable risk of contracting coronavirus.

A major growth restraint is a fact that cardiovascular devices have a high cost. For heart transplants, ventricular support devices particularly left ventricular support machines, are commonly applied. Although these are regarded as life-saving technologies, they do come with a number of drawbacks. By 6 months after installation, up to 55% of patients had experienced device-related problems. Nearly75% of patients had at least one unexpected reaction after one-and-half years. Emergency room visits to the hospital that were not scheduled are common. Individuals are transferred back to the hospital on average 2.5 times during their 10 months typical follow-up period. Device clotting, bleeding issues, nephrosis, hemorrhagic accidents, organ failure, and infections are all major non-surgical adverse reactions and consequences linked with these devices. If left untreated, some problems might be deadly to the victims.
Brugada Syndrome Market Segment Analysis:
By Treatment, the drug therapy segment is expected to grow at a CAGR of 6.1% in the previously mentioned forecast period. This growth can be attributed to the development and approval of different drugs in recent years.

For example, Amidst the coronavirus pandemic's unimaginable strain on healthcare services, the Food and Drug Administration's CDE Research approved new drug therapies, giving patients with a variety of ailments new hope for a better standard of living and, in some cases, better odds of surviving life-threatening illnesses. For individuals with uncommon disorders, several of these novel medicines have been authorized.

Drug therapy for severe diseases assist just 30 to 40% of patients, according to studies, and roughly 8% of hospitalized patients have adverse drug responses. The goal of personalizing pharmacological therapy is to enhance benefits while avoiding the risk of adverse responses owing to toxic effects or sub-therapeutic doses.
Brugada Syndrome Market Regional Insights:
For interventional cardiology, India, China, and Brazil are largely untouched territories. The high prevalence of diabetes and the big elderly population in these and other rising nations provide considerable development prospects for interventional cardiology equipment which is expected to influence the demand for Brugada syndrome treatment. As per the IDF, 75.0 million individuals in India had diabetes in 2022, with a projected increase to 102.4 million by 2031. Similarly, China's diabetes population is expected to grow to 145.6 million by 2031, up from 117.2 million in 2022. The fastest rise is projected in Asia-Pacific, owing to a greater emphasis on heart disease treatment and high demand for diagnostic testing. The alarming increase in pollution in this region is expected to increase heart disease and syndrome instances.

The objective of the report is to present a comprehensive analysis of the Brugada Syndrome market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants.

PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding the Brugada Syndrome market dynamics, structure by analyzing the market segments and projecting the Brugada Syndrome market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Brugada Syndrome market make the report investor’s guide.
Brugada Syndrome Market Scope: Inquire before buying



Global Brugada Syndrome Market


Report Coverage
Details


Base Year:
2022
Forecast Period:
2023-2029


Historical Data:
2018 to 2022
Market Size in 2022:
US $ 1.40 Bn.


Forecast Period 2023 to 2029 CAGR:
6.5%
Market Size in 2029:
US $ 2.18 Bn.


 Segments Covered:
by Treatment
Implantable cardioverter-defibrillator
Drug therapy


by Drugs
Antiarrhythmic drugs
Psychotropic drugs
Anesthetics/analgesics
Others


by End-User
Hospitals and clinics
Surgical centers
Diagnostic centers
Others



Brugada Syndrome Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Brugada Syndrome Market Key Players
1. Boston Scientific Corporation
2. LivaNova plc
3. Medtronic
4. Abbott
5. Edwards Lifesciences Corporation
6. Novartis AG
7. Sun Pharmaceutical Industries Ltd.
8. MRI Interventions
9. HeartSine Technologies LLC.
10.GeneDx
11.PGxHealth LLC
12.GE Healthcare
13.Pfizer, Inc
14.GlaxoSmithKline
15.Eli Lilly Company
16.Taj Pharmaceuticals Ltd

Frequently Asked Questions:

1. Which region has the largest share in Global Brugada Syndrome Market?
Ans: Asia Pacific region held the highest share in 2022.

2. What is the growth rate of Global Brugada Syndrome Market?
Ans: The Global Brugada Syndrome Market is growing at a CAGR of 6.5% during forecasting period 2023-2029.

3. What is scope of the Global Brugada Syndrome Market report?
Ans: Global Brugada Syndrome Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Brugada Syndrome Market?
Ans: The important key players in the Global Brugada Syndrome Market are – Boston Scientific Corporation, LivaNova plc, Medtronic, Abbott, Edwards Lifesciences Corporation, Novartis AG, Sun Pharmaceutical Industries Ltd., MRI Interventions, HeartSine Technologies LLC., GeneDx, PGxHealth LLC, GE Healthcare, Pfizer, Inc, GlaxoSmithKline, Eli Lilly Company, and Taj Pharmaceuticals Ltd

5. What is the study period of this Market?
Ans: The Global Brugada Syndrome Market is studied from 2022 to 2029.